東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

MicroRNA miR-29a is an oncomir in my...

Columbia University.

Linked to FindBook

Google Book

Amazon

博客來

MicroRNA miR-29a is an oncomir in myeloid leukemogenesis.

Record Type:	Electronic resources : Monograph/item
Title/Author:	MicroRNA miR-29a is an oncomir in myeloid leukemogenesis./
Author:	Han, Yoon-Chi.
Description:	130 p.
Notes:	Adviser: Hua Gu.
Contained By:	Dissertation Abstracts International69-10B.
Subject:	Biology, Microbiology. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3333353
ISBN:	9780549856498

MicroRNA miR-29a is an oncomir in myeloid leukemogenesis.
Han, Yoon-Chi.

MicroRNA miR-29a is an oncomir in myeloid leukemogenesis. - 130 p.

Adviser: Hua Gu.

Thesis (Ph.D.)--Columbia University, 2008.

MicroRNAs (miR) are short non-coding RNAs that negatively regulate gene expression by facilitating mRNA degradation or translational inhibition. Aberrant miRNA expression is well-documented in both solid and hematopoietic malignancies; however, there is limited evidence that a single miRNA is sufficient to induce cancer. Herein, we demonstrate that miR-29a is highly expressed in human and mouse hematopoietic stem cells (HSC) and human acute myeloid leukemia (AML) blasts but, down-regulated in normal committed progenitors. Ectopic expression of miR-29a in mouse HSC/progenitors is sufficient to induce a myeloproliferative disorder (MPD). During the MPD, miR-29a alters the composition of the most immature hematopoietic cells, significantly expedites cell cycle progression, and promotes proliferation of hematopoietic progenitors at the level of the multipotent progenitor (MPP). Furthermore, mice with miR-29a induced MPD progresses to acute myeloid leukemia (AML). The resulting AML contains a leukemia stem cell (LSC) population that can serially transplant disease with as few as 20 LSC. Gene expression analysis reveals multiple tumor suppressors and cell cycle regulators down-regulated in miR-29a expressing cells compared to wild type. We have identified Hbp1 as a bona fide miR-29a target, but knockdown of Hbp1 in vivo does not recapitulate the miR-29a phenotype in vivo, suggesting that additional genes are involved in the leukemogenic activity of miR-29a. These data indicate that miR-29a regulates early events in normal hematopoiesis and promotes myeloid expansion. Moreover, they also establish that aberrant expression of a single miRNA is sufficient to drive leukemogenesis, and suggest that therapeutic targeting of microRNAs may be an effective means of treating AML.

ISBN: 9780549856498Subjects--Topical Terms:

1017734
Biology, Microbiology.

MicroRNA miR-29a is an oncomir in myeloid leukemogenesis.
LDR:02613nmm 2200265 a 45 001 887212
005 20101020
008 101020s2008 ||||||||||||||||| ||eng d
020 $a 9780549856498
035 $a (UMI)AAI3333353
035 $a AAI3333353
040 $a UMI $c UMI
100 1 $a Han, Yoon-Chi. $3 1058941
245 1 0 $a MicroRNA miR-29a is an oncomir in myeloid leukemogenesis.
300 $a 130 p.
500 $a Adviser: Hua Gu.
500 $a Source: Dissertation Abstracts International, Volume: 69-10, Section: B, page: 5906.
502 $a Thesis (Ph.D.)--Columbia University, 2008.
520 $a MicroRNAs (miR) are short non-coding RNAs that negatively regulate gene expression by facilitating mRNA degradation or translational inhibition. Aberrant miRNA expression is well-documented in both solid and hematopoietic malignancies; however, there is limited evidence that a single miRNA is sufficient to induce cancer. Herein, we demonstrate that miR-29a is highly expressed in human and mouse hematopoietic stem cells (HSC) and human acute myeloid leukemia (AML) blasts but, down-regulated in normal committed progenitors. Ectopic expression of miR-29a in mouse HSC/progenitors is sufficient to induce a myeloproliferative disorder (MPD). During the MPD, miR-29a alters the composition of the most immature hematopoietic cells, significantly expedites cell cycle progression, and promotes proliferation of hematopoietic progenitors at the level of the multipotent progenitor (MPP). Furthermore, mice with miR-29a induced MPD progresses to acute myeloid leukemia (AML). The resulting AML contains a leukemia stem cell (LSC) population that can serially transplant disease with as few as 20 LSC. Gene expression analysis reveals multiple tumor suppressors and cell cycle regulators down-regulated in miR-29a expressing cells compared to wild type. We have identified Hbp1 as a bona fide miR-29a target, but knockdown of Hbp1 in vivo does not recapitulate the miR-29a phenotype in vivo, suggesting that additional genes are involved in the leukemogenic activity of miR-29a. These data indicate that miR-29a regulates early events in normal hematopoiesis and promotes myeloid expansion. Moreover, they also establish that aberrant expression of a single miRNA is sufficient to drive leukemogenesis, and suggest that therapeutic targeting of microRNAs may be an effective means of treating AML.
590 $a School code: 0054.
650 4 $a Biology, Microbiology. $3 1017734
690 $a 0410
710 2 $a Columbia University. $3 571054
773 0 $t Dissertation Abstracts International $g 69-10B.
790 $a 0054
790 1 0 $a Gu, Hua, $e advisor
791 $a Ph.D.
792 $a 2008
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3333353